Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours
Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours
复制标题
DOI：
10.1111/j.1365-2990.2004.00557.x
复制
发表时间：
2004-10-01
影响因子：
5
通讯作者：
Nixon, R
中科院分区：
文献类型：
--
作者：
Neuwelt, EA;Várallyay, P;Nixon, R
目的：Ferumoxtran-10（Combidex（（R）是一种葡聚糖涂层氧化铁纳米颗粒，通过磁共振（MR）可增强颅内肿瘤超过24小时，并可通过铁染色进行组织学成像。我们的目标是比较ferumoxtran成像和组织化学与钆增强恶性脑肿瘤的术前和术后MR。方法：7例原发性和转移性恶性肿瘤进行了MRI成像与钆和ferumoxtran术前和术后。在感兴趣的代表性区域中测定ferumoxtran增强扫描的归一化信号强度。对6名ferumoxtran患者和3名未接受ferumoxtran的患者的切除组织进行了评估，以确定肿瘤和反应性脑中铁的定位。结果如下：所有恶性肿瘤（均经钆MR增强）均显示ferumoxtran蓄积伴T1和T2信号变化，即使在1例患者中使用0.15 T术中MR装置。铁染色主要在反应性细胞（反应性星形胶质细胞和巨噬细胞）而不是肿瘤细胞中。在7例患者中的5例（包括2例显示其他病变的患者）中，观察到ferumoxtran增强区域，但钆未增强。术前和术后MR的比较显示7例中有4例残留ferumoxtran增强区。结论：在恶性肿瘤中，ferumoxtran可能显示增强区域，即使使用0.15 T术中MR，钆也不会增强。Ferumoxtran增强病变的T1信号强度持续增加2-5天，这可能为术后成像提供优于钆的优势。铁的组织化学显示ferumoxtran在反应性细胞（星形胶质细胞和巨噬细胞）而不是肿瘤细胞中摄取。
Objective: Ferumoxtran-10 (Combidex((R))), a dextran-coated iron oxide nanoparticle, provides enhancement of intracranial tumours by magnetic resonance (MR) for more than 24 h and can be imaged histologically by iron staining. Our goal was to compare ferumoxtran imaging and histochemistry vs. gadolinium enhancement in malignant brain tumours on preoperative and postoperative MR. Methods: Seven patients with primary and metastatic malignant tumours underwent MR imaging with gadolinium and ferumoxtran both pre- and postoperatively. Normalized signal intensities on the ferumoxtran-enhanced scans were determined in representative regions of interest. Resected tissue from six ferumoxtran patients and from three patients who did not receive ferumoxtran was assessed for localization of iron in tumour and reactive brain. Results: All malignant tumours (all of which enhanced by gadolinium MR) showed ferumoxtran accumulation with T1 and T2 signal changes, even using a 0.15 T intraoperative MR unit in one patient. Iron staining was predominantly in reactive cells (reactive astrocytes and macrophages) and not tumour cells. In five of the seven patients, including two patients who showed additional lesions, areas enhancing with ferumoxtran but not with gadolinium were observed. Comparison of the pre- and postoperative MR revealed residual ferumoxtran-enhancing areas in four of seven cases. Conclusion: In malignant tumours, ferumoxtran may show areas of enhancement, even with a 0.15 T intraoperative MR, that do not enhance with gadolinium. Ferumoxtran-enhancing lesions have persistent increased T1 signal intensity for 2-5 days, which may provide advantages over gadolinium for postoperative imaging. Histochemistry for iron shows uptake of ferumoxtran in reactive cells (astrocytes and macrophages) rather than tumour cells.